Selection_NN
and_CC
long-term_JJ
persistence_NN
of_IN
reactive_JJ
CTL_NN
clones_NNS
during_IN
an_DT
EBV_NN
chronic_JJ
response_NN
are_VBP
determined_VBN
by_IN
avidity_NN
,_,
CD8_NN
variable_JJ
contribution_NN
compensating_VBG
for_IN
differences_NNS
in_IN
TCR_NN
affinities_NNS
._.

Recent_JJ
studies_NNS
have_VBP
suggested_VBN
that_IN
the_DT
diversity_NN
of_IN
TCR_NN
repertoire_NN
after_IN
primary_JJ
immunization_NN
is_VBZ
conserved_VBN
in_IN
memory_NN
T_NN
cells_NNS
and_CC
that_IN
a_DT
progressive_JJ
narrowing_NN
of_IN
this_DT
repertoire_NN
may_MD
take_VB
place_NN
during_IN
recall_NN
infections_NNS
._.

It_PRP
now_RB
remains_VBZ
to_TO
be_VB
investigated_VBN
which_WDT
parameters_NNS
determine_VBP
the_DT
repertoire_NN
of_IN
the_DT
memory_NN
response_NN
and_CC
possibly_RB
restrict_VB
its_PRP$
diversity_NN
after_IN
subsequent_JJ
antigenic_JJ
challenges_NNS
._.

To_TO
address_VB
this_DT
question_NN
,_,
we_PRP
took_VBD
advantage_NN
of_IN
a_DT
panel_NN
of_IN
CD8_NN
+_CC
T_NN
cell_NN
clones_NNS
from_IN
the_DT
joint_NN
of_IN
a_DT
rheumatoid_JJ
arthritis_NN
patient_NN
and_CC
selected_VBD
for_IN
their_PRP$
reactivity_NN
against_IN
a_DT
single_JJ
MHC\/peptide_NN
complex_NN
._.

Characterization_NN
of_IN
both_DT
TCR_NN
chains_NNS
documented_VBD
a_DT
great_JJ
diversity_NN
among_IN
those_DT
clones_NNS
and_CC
the_DT
persistence_NN
of_IN
clonotypes_NNS
over_IN
a_DT
2-yr_JJ
period_NN
._.

Strikingly_RB
,_,
despite_IN
the_DT
observed_VBN
repertoire_NN
heterogeneity_NN
,_,
all_DT
clones_NNS
displayed_VBD
a_DT
narrow_JJ
range_NN
of_IN
MHC\/peptide_NN
density_NN
requirements_NNS
in_IN
cytotoxicity_NN
assays_NNS
-LRB-_-LRB-
ED50_NN
between_IN
9_CD
and_CC
36_CD
nM_NN
-RRB-_-RRB-
._.

TCR_NN
affinities_NNS
were_VBD
then_RB
indirectly_RB
estimated_VBN
by_IN
blocking_VBG
CD8_NN
interaction_NN
with_IN
an_DT
anti-CD8_JJ
mAb_NN
._.

We_PRP
found_VBD
a_DT
wide_JJ
range_NN
of_IN
TCR_NN
affinities_NNS
among_IN
the_DT
different_JJ
clonotypes_NNS
that_WDT
segregated_VBD
with_IN
Vbeta_NN
usage_NN
._.

We_PRP
thus_RB
propose_VBP
that_IN
during_IN
an_DT
in_FW
vivo_FW
chronic_JJ
response_NN
,_,
a_DT
narrow_JJ
range_NN
of_IN
avidity_NN
of_IN
the_DT
TCR-CD8_NN
complex_NN
conditions_VBZ
long-term_JJ
clonotype_NN
persistence_NN
,_,
and_CC
that_IN
the_DT
level_NN
of_IN
CD8_NN
contribution_NN
is_VBZ
adjusted_VBN
to_TO
keep_VB
clonotypes_NNS
with_IN
variable_JJ
TCR_NN
affinities_NNS
within_IN
this_DT
avidity_NN
window_NN
._.

